Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Monosodium Glutamate (MSG) to Reduce Salivary Gland and Renal Accumulation of PSMA-binding Radiopharmaceuticals

NCT03693742 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT03693742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Monosodium Glutamate (MSG) to Reduce Salivary Gland and Renal Accumulation of PSMA-binding Radiopharmaceuticals
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Completed
Start date
November 4, 2019
Completion date
May 8, 2020
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer metastatic, prostatic neoplasm